The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate-limiting step in cholesterol biosynthesis and has proven to be an effective target of lipid-lowering drugs, statins. The aim of this study was to understand the role of hepatic HMGCR in vivo. Methods and Results-To disrupt the HMGCR gene in liver, we generated mice homozygous for a floxed HMGCR allele and heterozygous for a transgene encoding Cre recombinase under the control of the albumin promoter (liver-specific HMGCR knockout mice). Ninety-six percent of male and 71% of female mice died by 6 weeks of age, probably as a result of liver failure or hypoglycemia. At 5 weeks of age, liver-specific HMGCR knockout mice showed severe hepatic steatosis with apoptotic cells, hypercholesterolemia, and hypoglycemia. The hepatic steatosis and death were completely reversed by providing the animals with mevalonate, indicating its essential role in normal liver function. There was a modest decrease in hepatic cholesterol synthesis in liver-specific HMGCR knockout mice. Instead, they showed a robust increase in the fatty acid synthesis, independent of sterol regulatory element binding protein-1c. Conclusion-Hepatocyte HMGCR is essential for the survival of mice, and its abrogation elicits hepatic steatosis with jaundice and hypoglycemia. (Arterioscler Thromb Vasc Biol. 2012;32:1824-1831.)
T he mevalonate pathway produces isoprenoids that are essential for the diverse cellular functions ranging from cholesterol synthesis to growth control. The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) (EC 1.1.1.34), which catalyzes the conversion of HMG-coenzyme A to mevalonate, is the rate-limiting enzyme in the mevalonate pathway. 1 Mammalian HMGCR is an integral high-mannose glycoprotein of the endoplasmic reticulum (ER). 2 Structurally, it is divided into 2 major domains: a C-terminal cytosolfacing domain that tetramerizes to form the active site and an N-terminal hydrophobic region that spans the ER membrane 8× and bears a single N-glycan. This membrane region is dispensable for the enzymatic activity but necessary for the metabolically controlled stability of the enzyme and sufficient to cause sterol-accelerated degradation of heterologous proteins. Within this region, transmembrane spans 2 through 6 bear significant sequence homology to the corresponding transmembrane spans of sterol regulatory element binding protein (SREBP) cleavage-activating protein (SCAP). 3 To ensure a steady supply of mevalonate, the nonsterol and sterol end products of the mevalonate metabolism exert feedback regulatory effects on the activity of this enzyme through multivalent mechanisms, including inhibition of the transcription of its RNA, blocking of translation, and acceleration of the protein's degradation by a mechanism called ER-associated degradation, thereby regulating the amount of protein over a several hundred-fold range. ER-associated degradation of HMGCR requires the binding of Insig-1 to the sterol-sensing domain. 4 Despite the critical role of HMGCR in cholesterol biosynthesis, little is known about its relevance to diseases. Only recently, HMGCR has been identified as a determinant of plasma cholesterol levels. 5 Inhibitors of HMGCR, statins, are potent cholesterollowering agents that have been widely used to prevent the occurrence of coronary heart disease and other atherosclerotic diseases. 6 The atheroprotective properties of statins are primarily because of the potent low-density lipoprotein (LDL)cholesterol-lowering effect. 7 Statins have also been reported to exert cholesterol-independent, or so-called pleiotropic, effects that involve improving endothelial function and decreasing oxidative stress and vascular inflammation. 8 The benefits of statins extend beyond cardiovascular diseases and include a reduction in the risk of dementia, Alzheimer disease, ischemic stroke, osteoporosis, tumor growth, and viral infection. Most of these pleiotropic effects are mediated by an ability to block the synthesis of nonsterol isoprenoid intermediates. Statins have toxic effects in only a limited number of patients and are generally considered safe.
To establish an animal model for investigating the mechanisms behind the effects, including toxicity of statins, we have generated HMGCR knockout (KO) mice lacking the enzyme throughout their bodies. 9 These mice die in a relatively early stage of embryonic development (ie, before E8.5). Because mice lacking squalene synthase, the first committed enzyme in the sterol pathway, die in the embryonic stage with apparent anomalies of the development of the central nervous system, 10 we took advantage of the tissue-specific gene targeting using the Cre-loxP system to generate mice lacking HMGCR in a liver-specific manner.
Materials and Methods
Liver-specific HMGCRKO (L-HMGCRKO) mice were generated by cross-breeding heterozygous floxed HMGCR (referred to as HMGCR +/f ; f denotes floxed) mice with transgenic mice expressing Cre recombinase under the control of albumin gene promoter (Alb-Cre). 11, 12 All animal experiments were performed with the approval of the Institutional Animal Care and Research Advisory Committee at Jichi Medical University. For detailed protocols for the generation of L-HMGCRKO mice and other experimental procedures, please refer to the online-only Data Supplement.
Results
Because there were no differences in growth curves or metabolic parameters, such as plasma lipid and glucose levels, among the HMGCR +/+ (wild-type), HMGCR +/+ Alb-Cre (CRE), and HMGCR f/f (fHMGCR) mice, we used fHMGCR mice as a control. To determine whether the expression of the HMGCR gene was abrogated in the liver, we performed a Southern blot ( Figure 1A ), Northern blot ( Figure 1B) , and real-time polymerase chain reaction ( Figure 1C) . The Southern blot analysis shows that only the 6.3-kb wild-type allele and 7.7kb floxed allele were observed in the DNA from liver in wildtype and fHMGCR mice, respectively. In L-HMGCRKO mice at 3 weeks, the liver contained predominantly the 12.0-kb KO allele (70% based on PhosphorImager analysis [BAS  200 , Fujifilm, Tokyo, Japan]) and some residual floxed allele (30%). The mRNA expression of HMGCR in the liver of L-HMGCRKO mice was decreased to 30% of the fHMGCR mice at 3 weeks of age and to <10% at 4 and 5 weeks upon Northern blot analysis. The time-dependent abrogation of the mRNA expression of HMGCR was also confirmed by realtime polymerase chain reaction. Based on this method, the mRNA levels were decreased to only 2% of the fHMGCR mice at 4 and 5 weeks, although there were no significant differences in other organs ( Figure IIA in the online-only Data Supplement). Immunoblot analysis showed that the amount of HMGCR protein in the liver of L-HMGCRKO mice was 15% of that in fHMGCR mice ( Figure 1D ). Despite the profound reduction in HMGCR at both the mRNA and protein levels, the HMGCR activity in the liver of L-HMGCRKO mice was decreased by only 44% compared with that in fHMGCR mice ( Figure 1E ). To determine whether HMGCR is specifically abrogated in the liver parenchymal cells of L-HMGCRKO mice, we separated parenchymal and nonparenchymal cells from the liver at 3 weeks of age by density-gradient centrifugation after liver perfusion with collagenase. The mRNA expression of HMGCR in the parenchymal cells of L-HMGCRKO mice was decreased by 70.6% compared with that in fHMGCR mice, whereas the mRNA expression of HMGCR in the nonparenchymal cells was not different between the fHMGCR and L-HMGCRKO mice at 3 weeks of age ( Figure and liver-specific HMGCR knockout (L-HMGCRKO) mice at 3 weeks of age as described in the online-only Data Supplement. B, Northern blot analysis of hepatic RNA from the livers of fHMGCR and L-HMGCRKO mice at 3, 4, and 5 weeks of age. Aliquots (20 μg) of total RNA from liver were subjected to electrophoresis and blot hybridization with 32 P-labeled cDNA probes for mouse HMGCR as described in the online-only Data Supplement. C, Quantitative real-time polymerase chain reaction of HMGCR mRNA levels from the livers of mice indicated in B (n=5 in each group). D, Immunoblot analysis of HMGCR protein from the livers of control and L-HMGCRKO mice at 4 weeks of age (n=3 in each group). Aliquots (50 μg) of liver membrane fractions were subjected to SDS-PAGE and immunoblot analysis. The membrane protein transferrin receptor was used as a loading control. E, HMGCR activity in the liver microsomal fractions of fHMGCR and L-HMGCRKO mice at 4 weeks of age (n=5 in each group). F, The survival curves were generated by the Kaplan-Meier method, and differences among the survival rates were compared using the χ 2 method. Male (n=25) and female (n=42) L-HMGCRKO mice were followed for >100 days. Each value represents mean±SD. Significant differences compared with control mice: *P<0.05 and **P<0.001. online-only Data Supplement). HMGCR activity in the parenchymal cells of L-HMGCRKO mice was decreased by only 47% compared with that in fHMGCR mice ( Figure IID in the online-only Data Supplement). The relative decreases in the mRNA and activity of HMGCR in the parencymal cells were similar to those observed in the whole liver of L-HMGCRKO mice ( Figure 1C and E), supporting that HMGCR gene was specifically abrogated in the parenchymal cells of the liver and that there was no compensatory upregulation of HMGCR in the nonparenchymal cells of the L-HMGCRKO mice.
L-HMGCRKO mice were born at a rate in accordance with the rule of Mendelian inheritance. However, 96% of males died with a median survival time of 35 days, whereas 71% of females died with a median survival time of 36 days ( Figure 1F ), and the rest of them survived until 12 months of age. Therefore, the survival rate of females was significantly higher than males (P=0.025). The mRNA expression levels of HMGCR in the liver from the surviving HMGCRKO mice were as high as those from fHMGCR mice ( Figure IIB in the online-only Data Supplement). Next, we compared body weight, liver weight, plasma lipid levels, liver functions, and blood glucose levels between fHMGCR and L-HMGCRKO mice (Table) . Although the body weight of L-HMGCRKO mice was not different from that of fHMGCR mice at 3 weeks of age, it decreased by 10% at 4 weeks and by 38% at 5 weeks of age. Liver weight did not differ between the 2 groups. However, the ratio of liver weight to body weight was increased by 39% and 74% at 4 and 5 weeks of age, respectively. The livers of L-HMGCRKO mice were enlarged, paler, and whiter than those of fHMGCR mice at 5 weeks of age (Figure 2A and 2B). Consistent with the macroscopic abnormalities of the liver, plasma levels of aspartate aminotransferase, alanine transaminase, and bilirubin were markedly increased in the L-HMGCRKO mice compared with fHMGCR mice at 5 weeks of age. Total cholesterol levels in the plasma were decreased in the L-HMGCRKO mice by 26% at 3 weeks of age (Table) . In parallel, plasma concentrations of LDL cholesterol and apolipoprotein (apo) B-100 protein were decreased ( Figure IIIA and IIIE in the online-only Data Supplement). Despite the liver failure of L-HMGCRKO mice at 5 weeks of age, the plasma levels of cholesterol, free cholesterol, and phospholipids were increased 4.3-, 7.9-, and 4.0-fold, respectively. On the other hand, plasma cholesterol ester levels were decreased by 38% (Table) . Therefore, calculated ratios of free cholesterol to cholesterol ester were increased 13-fold. Most of the increased cholesterol was distributed in the size of very low-density lipoprotein through LDL ( Figure IIIC in the online-only Data Supplement). Although apoB-100 levels were decreased, apoB-48 levels were substantially increased in the plasma of L-HMGCRKO mice at 5 weeks of age ( Figure IIIG in the online-only Data Supplement). These findings together with the results of agar gel electrophoresis of the plasma (Figure III-I in the online-only Data Supplement) strongly indicate that both lipoprotein X and apoB-48-containing lipoproteins were increased in the L-HMGCRKO mice. Hepatic LDL receptor protein levels were not altered between fHMGCR and L-HMGCRKO mice at 3 and 5 weeks of age ( Figure IIIF and IIIH in the online-only Data Supplement), despite increased hepatic LDL receptor mRNA levels ( Figure 4A ). Plasma lipoprotein changes in L-HMGCRKO mice may not be influenced by LDL receptor protein levels. Plasma free fatty acid levels were also increased 3.1-fold at 5 weeks. In contrast, plasma triglyceride levels were decreased by 69% and 70% at 4 and 5 weeks of age, respectively. It is of note that L-HMRCRKO mice were moderately hypoglycemic at 5 weeks.
To determine the causes of the liver dysfunction associated with hepatomegaly, we performed a microscopic analysis of the liver (Figure 2 ). Hematoxylin and eosin staining revealed moderate to severe ballooning and unicellular necrosis of parenchymal cells at 5 weeks ( Figure 2C and 2D ). Oil-red O staining showed moderate to severe microvesicular steatosis of the parenchymal cells ( Figure  2E and 2F). TdT-mediated dUTP-nick end labeling-positive ( Figure 2G , 2H, and 2M) and Ki-67-positive parenchymal cells Blood samples were taken from male mice fed a normal chow diet ad libitum before the study. Each value represents the mean±SD. Significant differences compared with control mice: *P<0.05, **P<0.01, and ***P<0.001. HMGCR indicates 3-hydroxy-3-methylglutaryl-coenzyme A reductase; L-HMGCRKO, liver-specific HMGCR knockout mice; fHMGCR, floxed HMGCR.
( Figure 2I , 2J, and 2N) were significantly increased 11-and 2.8fold in the liver of L-HMGCRKO mice compared with that in fHMGCR mice, respectively. The liver of L-HMGCRKO mice contained increased amounts of type 4 collagen ( Figure 2K and 2L). Caspase 3 activity in the liver of L-HMGCRKO mice was also increased 1.8-fold compared with that of fHMGCR ( Figure VA To determine whether the liver-specific abrogation of HMGCR affected cholesterol metabolism in the liver, we measured the hepatic levels of cholesterol and triglycerides ( Figure  3 ). The hepatic cholesterol content was decreased by only 22% in the L-HMGCRKO mice compared with the fHMGCR mice ( Figure 3A) . Unexpectedly, the hepatic contents of triglyceride were increased 2-fold ( Figure 3B ). These results indicate that the neutral lipids stained with oil-red O in the liver were primarily triglycerides. The reduction in the cholesterol contents of the liver was smaller than expected. We measured cholesterol synthesis in liver slices in culture ( Figure 3C ). The cholesterol synthesis was reduced by 45%. This reduction paralleled the degree of reduction in HMGCR activity in the liver ( Figure 1E ). We also measured the amounts of fatty acids synthesized in the liver ( Figure 3D) . Surprisingly, the synthesis of fatty acids from acetate was markedly increased 17-fold in the liver of L-HMGCRKO mice. Although total amounts of fatty acids were not different between the 2 mice ( Figure 3E ), the following fatty acid species were significantly increased in the liver of L-HMGCRKO mice: C18:0, C18:1n-9, C20:1n-9, C20:3n-9, and C22:4n-6 ( Figure 3F) . Given the increased production of fatty acids and triglycerides in the liver, we measured other metabolites of fatty acids such as diglycerides and ceramides. The hepatic levels of diglycerides were increased 1.8-fold ( Figure 3G ), but those of ceramides were not increased significantly ( Figure 3H) .
To clarify the mechanisms behind the changes in fatty acid metabolism, we determined the changes in the levels of mRNA expression in various genes involved in cholesterol or fatty acid metabolism in the liver at 4 weeks of age by real-time polymerase chain reaction ( Figure 4A) . As to the genes involved in cholesterol metabolism, the mRNA levels of SREBP2, LDL receptor, proprotein convertase subtilisin/kexin type 9, and squalene synthase were increased 1.4-, 1.9-, 2.8-, and 3.9-fold, respectively. On the other hand, the mRNA levels of cholesterol 7α-hydroxylase, a rate-limiting enzyme for bile acid synthesis, were decreased by 60%. With regard to the genes involved in fatty acid metabolism, the mRNA levels of fatty acid synthase (FAS), acetyl-CoA carboxylase, and stearoyl-CoA desaturase 2 were increased 2.4-, 1.4-, and 22-fold, respectively. On the other hand, the mRNA expression of SREBP1c and acyl CoA:diacylglycerol acyltransferase 2 was decreased by 80% and 40%, respectively. There were no changes in either the mRNA expression of SREBP1a, a splice variant of SREBP1c, or liver X receptor α (LXRα), an important transcriptional activator of the SREBP1c gene. The mRNA expression of peroxisome proliferator-activated receptor α, a transcription regulator of genes for fatty acid oxidation, was not changed.
HMGCR catalyzes the formation of mevalonate, which is used as a substrate for the synthesis not only of cholesterol but also nonsterols such as isoprenoids, ubiquinone, heme A, and dolichol. To test the notion that death, likely because of severe liver failure, was caused by the alteration of a nonsterol pathway, we evaluated the isoprenylation of small GTP-binding proteins such as H-Ras and Rac1 by measuring the amount of membrane-bound forms ( Figure 4B ). The ratio of the membrane-bound form to the cytosolic form of H-Ras or Rac1 was decreased to 0.05 to 0.2 compared with control. These results indicate that the deficiency of HMGCR affected the nonsterol pathway more severely than the sterol pathway. We also estimated changes in intracellular signaling molecules ( Figure 4C ). p-Akt and c-Met were decreased by 72% and 81%, respectively, whereas phospho-signal transducer and activator of transcription 3 was increased 7.6-fold.
If the lethal phenotype of HMGCR deficiency is because of the deficiency of mevalonate, supplementation with mevalonate could theoretically rescue the lethal phenotype. In fact, providing the male mice with water containing mevalonate significantly attenuated the liver dysfunction and hypercholesterolemia ( Figure 5A-5C) . The pathological abnormalities observed in the male L-HMGCRKO mice were almost normalized by the supplementation with mevalonate ( Figure 5D-5G) . Consistently, the amounts of the membrane-bound form of H-Ras or Rac 1 were restored to normal levels ( Figure 5H ). Similar improvements were found in female L-HMGCRKO mice (data not shown). No death occurred until 40 days of age in L-HMGCRKO mice supplemented with mevalonate.
Because L-HMGCRKO mice were hypoglycemic (Table) , it is possible that hypoglycemia is the direct cause of death. To test this hypothesis, we allowed mice free access to drinking water containing 20% (w/v) glucose. Glucose feeding significantly increased plasma glucose levels (43. 5 
Discussion
Nearly all the male L-HMGCRKO mice died before 40 days of age, whereas 30% of females survived until 12 months of age. Before their death, the mice developed severe hepatic damage with hepatomegaly, steatosis, and hypoglycemia. Thus, we ascribe the lethal effect of the liver-specific deficiency of HMGCR to the hepatic toxicity and hypoglycemia. Unexpectedly, the mice developed hypercholesterolemia before death, although hepatic cholesterol synthesis was significantly reduced. This lethal phenotype was completely reversed by mevalonate or glucose, indicating that mevalonate is essential for the survival of mice and that hypoglycemia is the direct cause of lethality.
The mRNA expression of HMGCR was reduced as early as 3 weeks of age and almost undetectable at 4 weeks. This developmental reduction in the expression is consistent with the developmental induction of the expression of albumin. Other liver-specific KO models using Alb-Cre showed abrogation of the expression of reporter genes at a similar stage. 12 However, the HMGCR activity of the liver was reduced by only 50%. Because the parenchymal hepatocytes from the liver of the L-HMGCRKO mice at 3 weeks of age expressed substantial HMGCR activity, we speculate that most of the activity is derived from upregulated HMGCR expression in a certain subset of hepatocytes that escaped from HMGCR gene inactivation. Indeed, recombination efficiency was only 75% at weaning, 13 and HMGCR protein can be increased 25-fold at the posttranscriptional level. 1 Figure 4 . Relative amounts of various mRNAs and degree of isoprenylation of small GTP-binding proteins and liver regeneration-associated proteins in the livers of control and liver-specific HMGCR knockout (L-HMGCRKO) male mice at 4 weeks of age. A, Total RNA from the livers of mice (n=5 in each group) was subjected to quantitative real-time polymerase chain reaction as described in the online-only Data Supplement. Each value represents the amount of mRNA relative to that in the control mice, which is arbitrarily defined as 1. B, Liver membranous and cytosolic fractions for small GTP-binding proteins or (C) liver tissue lysates for liver regenerationassociated proteins were prepared as described in the online-only Data Supplement (n=3 in each group), and aliquots (30 μg) were subjected to SDS-PAGE and immunoblot analysis. Each value represents mean±SD. Significant differences compared with control mice: *P<0.05 and **P<0.01. LDLR indicates low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; FAS, fatty acid synthase; DGAT, diacylglycerol acyltransferase; SCD, stearoyl-CoA desaturase; LXR α, liver X receptor; PPARα, peroxisome proliferator-activated receptor α; SS, squalene synthase; MTP, microsomal triglyceride transfer protein; CYP7A1, cholesterol 7α-hydroxylase; ACC, acetyl-CoA carboxylase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; STAT3, signal transducer and activator of transcription 3.
Figure 5.
Supplementation of mevalonate. Male mice were given mevalonate in drinking water at a concentration of 5 mmol/L from the age of 28 days to 35 days (n=5 in each group). After supplementation, plasma alanaine transaminase (ALT) (A), total bilirubin (B), and total cholesterol (C) levels were measured. The livers were removed from liver-specific HMGCR knockout (L-HMGCRKO) mice not supplemented with mevalonate (−; D and F, respectively) or supplemented with mevalonate (+; E and G, respectively) stained with hematoxylin and eosin or oil-red O. H, Immunoblot analyses for small GTP-binding proteins in membranous and cytosolic fractions of the liver. Each value represents mean±SD. Significant differences compared with control mice: *P<0.001. Furthermore, there might be time lag between disappearance of HMGCR protein and cessation of transcription.
Sex dimorphism in lethality is noteworthy. The present results that male L-HMGCRKO mice were more prone to die than females are consistent with the general view that females are more resistant to morbidity and mortality of various liver diseases than males. 14 In addition to protection against liver injury via vasodilating and anti-inflammatory effects, estrogen itself attenuates the development of hepatic steatosis. 15 The mRNA expression levels of HMGCR in the liver of the surviving L-HMGCRKO mice were indistinguishable from those of fHMGCR mice ( Figure IIB in the online-only Data Supplement). It is likely that the hepatocytes with a relatively intact HMGCR gene may be extensively regenerated, thereby eventually compensating for the KO in the survivors. In support of this, several Ki-67-positive cells were greatly increased in the L-HMGCRKO mice ( Figure 2L and 2N) .
Hepatic cholesterol levels were mildly decreased, and the decrease in plasma cholesterol levels was modest in the L-HMGCRKO mice at 3 weeks of age. More surprisingly, the plasma cholesterol levels even increased immediately before death. Extrahepatic organs with high cholesterol synthesis, such as skin, bowels, and muscles, may be a source of cholesterol in the plasma. 16 The hypercholesterolemia before death appears paradoxical, given the failure of cholesterol synthesis in the hepatocytes. At this stage, the mice develop jaundice. Because the physicochemical characteristics of the accumulated lipoproteins were similar to those of lipoprotein X, cholestasis may at least partly account for hypercholesterolemia. Simultaneous accumulation of both lipoprotein X and apoB48-containing particles has also been reported in rats with intrahepatic cholestasis. 17 Interestingly, L-HMGCRKO mice showed hepatic steatosis. Because hepatic triglyceride levels were increased 2-fold but hepatic cholesterol ester levels were not increased (data not shown) most of the neutral lipids stained with oil-red O are triglycerides. Supporting this, the synthesis of fatty acids was increased 17-fold. In this context, it is noteworthy that the expression of enzymes for fatty acid synthesis, FAS and stearoyl-CoA desaturase 2, was increased. In normal adults, stearoyl-CoA desaturase 1 is the major enzyme catalyzing desaturation of oleate, whereas stearoyl-CoA desaturase 2 is an isozyme that is transiently expressed in the liver in embryos and neonates and may be involved in lipogenesis at that developmental stage. 18 Indeed, the amounts of polyunsaturated fatty acids were increased in the liver ( Figure 3F ).
The increase in fatty acids synthesis appeared disproportionately larger than the increase in triglycerides in the liver. In this context, it is of note that the expression of diacylglycerol acyltransferase 1 was not increased and that of diacylglycerol acyltransferase 2 was even decreased. Thus, it is probable that the newly synthesized fatty acids were not used to produce triglycerides. Generally, the enzymes catalyzing fatty acid synthesis are transcriptionally induced by SREBP1c. However, the expression of SREBP1c was reduced 5-fold, suggesting that the increased lipogenesis was not mediated by SREBP1c. Similar SREBP1c-independent lipogenesis is reported in mice overexpressing a constitutively active form of Akt in the liver. 19 Furthermore, the levels of LXRα mRNA, a nuclear receptor that can stimulate SREBP1c gene expression 20 and can also directly stimulate transcription of FAS, 21 were not increased in the livers of L-HMGCRKO mice. We speculate that the lack of cholesterol reduces the supply of oxysterols, physiological ligands of LXR, which transactivates SREBP1c. 22 This notion is supported by the decreased expression of cholesterol 7α-hydroxylase and diacylglycerol acyltransferase 2, also targets of LXR.
In contrast to SREBP1c expression, the expression of SREBP2 was increased, conceivably accounting for the increased expression of its targets: the LDL receptor and squalene synthase. The expression of FAS in the face of significant suppression of SREBP1c or unaltered LXRα suggests a regulatory pathway independent of SREBP1c or LXRα. Recently, a decrease in farnesyl pyrophosphate or farnesol has been shown to induce the expression of FAS independently of SREBP1c. 23 The liver of the L-HMGCRKO mice contained increased numbers of TdT-mediated dUTP-nick end labeling-positive cells. Consistent with the apoptotic nature of the cell death, the activity of caspase 3, a final executer of apoptosis which cleaves to induce the release of cytochrome c from mitochondria, was increased in the liver of the L-HMGCRKO mice. We have hypothesized several potential mechanisms for apoptosis: accumulation of toxic lipid metabolites 24 and reduction of survival factors. 25 However, we failed to obtain evidence for the involvement of ceramide and survivin in apoptosis.
As predicted, membrane-bound forms of Ras and Rac1 were significantly reduced, conceivably as a result of the defect in their isoprenylation. Several mechanisms linking the defect in isoprenylation to apoptosis have been proposed. For example, Rac1 is reported to protect against apoptosis by stimulating nicotinamide adenine dinucleotide phosphate-oxidase, thereby increasing the levels of reactive oxygen species. 26 However, we failed to detect a decrease in H 2 O 2 levels in the liver.
During the search for the plausible mechanism of the hepatocyte apoptosis, we found a significant increase in the mRNA level of C/EBP-homologous protein, a hallmark of the ER stress response and inducer of apoptosis, in the liver of L-HMHCRKO mice. Because hepatic steatosis induces ER stress, it is reasonable to speculate that the increased synthesis of fatty acids causes hepatic lipoapoptosis via increasing the C/EBP-homologous protein. The liver of L-HMGCRKO mice had significantly decreased levels of either p-Akt or c-met protein. Because hepatocyte growth factor exerts prosurvival effects mainly through activating phosphatidylinositol-3 kinase/Akt pathway after binding to its receptor, c-met, 27 defective hepatocyte growth factor signaling may play a salutary role in the induction of hepatocyte apoptosis. The increase in phospho-signal transducer and activator of transcription 3 might be a compensatory response secondary to increased apoptosis, but failed to overcome it. Similar failure to compensate the liver failure by activated signal transducer and activator of transcription 3 was reported in mice deficient in phosphoinositide-dependent protein kinase 1. 28 These phenotypes of L-HMGCRKO mice should be discussed in relation to other mouse models of genetic disorders of cholesterol metabolism. Thus far, 2 models have been reported to survive the perinatal period, despite reduced cholesterol biosynthesis in the liver. Because the global disruption of SREBP cleavage-activating protein and site 1 protease is embryonic lethal, as is the case for HMGCR, liver-specific KO mice have been generated. In both the liver-specific SREBP cleavage-activating protein 29 and site 1 protease KO mice, 30 the synthesis of cholesterol as well as fatty acids was significantly reduced in the liver. Neither mouse, however, died of liver toxicity, probably because the reduction in the expression of HMGCR was not as severe as in L-HMGCRKO mice.
In conclusion, HMGCR is essential for the survival of mice. Despite the defect in hepatic cholesterol biosynthesis in L-HMGCRKO mice, the homeostasis of cholesterol in the liver and plasma is surprisingly well maintained presumably via compensatory changes in the flux of cholesterol and fatty acids. These results might provide insight for understanding the role of cholesterol biosynthetic pathway in the normal function of hepatocytes.
